lixisenatide vs Semaglutide (Ozempic)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

lixisenatide · Adlyxin / Lyxumia

Marketed by Sanofi and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT00707031 · Phase 3 · completed

The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)

Result source: NCT00707031

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointlixisenatideSemaglutide (Ozempic)
HbA1c, change-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
Body weight, change (kg)-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
HbA1c below 7%53% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Fasting plasma glucose, change-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
3-point MACE (% with event)—Not reported6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153

HbA1c, change

lixisenatide
-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473
Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450

Body weight, change (kg)

lixisenatide
-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352

HbA1c below 7%

lixisenatide
53% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937
Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484

Fasting plasma glucose, change

lixisenatide
-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504
Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984

3-point MACE (% with event)

lixisenatide
—Not reported
Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
15 other shared endpoints and safety

Coverage. lixisenatide: 19 of 19 rows · Semaglutide (Ozempic): 19 of 19 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriclixisenatide
Rows use multiple source trials
Semaglutide (Ozempic)
Rows use multiple source trials
DTSQ-c
absolute change · score
0.88 vs 0.65 placebo score @ 24wka,b,c
NCT00975286 · Phase 3 · registry result, not featured evidence
4.55 vs 4.52 Dulaglutide score @ 40wk1.0 mgd,a,b,c
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
4.6 vs 4.52 Dulaglutide score @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.57 mmol/L @ 24wkd,e,a,b
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.35 mmol/L @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-1.45 mmol/L @ 24wk*e,a,b
NCT05533632 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -26.2 mg/dL as posted
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.74% (n=222) @ 24wkd,e,a,b
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.65% (n=218) @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-1.6% (n=92) @ 24wke,a,b
NCT05533632 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
responder rate · % of participants
19.9% (n=366) vs 9% (n=365) Insulin Glargine @ 30wkf,a,b
NCT02058160 · Phase 3 · registry result, not featured evidence
2 other source trials
31.8% (n=468) vs 18.9% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
26.2% (n=233) vs 18.9% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
76.9% (n=238) vs 33.7% (n=249) Sitagliptin @ 30wk1.0 mg weeklyd,f,a,b
NCT03061214 · Phase 3 · registry result, not featured evidence
show 1 more dose
66% (n=235) vs 33.7% (n=249) Sitagliptin @ 30wk0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
40.6% (n=239) @ 24wkd,a,b,c
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
43% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
67.6% (n=480) @ 40wk2.0 mg weeklyd,a,b,c
NCT03989232 · Phase 3
show 1 more dose
57.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
28.5% (n=295) vs 35.4% (n=297) Exenatide @ 24wkf,a,g
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
9 other source trials
32.4% (n=185) vs 18.1% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
32.1% (n=215) vs 16.3% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
28.9% (n=308) vs 10.1% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
24% (n=150) vs 26.3% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
14.5% (n=304) vs 3.8% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
19.3% (n=544) vs 4.7% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
25.6% (n=156) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
20.4% (n=152) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
17.8% (n=146) vs 1.3% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wkf,a,g
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
No placebo or comparator arm
19.2% (n=239) @ 24wkd,a,b,c
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
23.8% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
51.7% (n=480) @ 40wk2.0 mg weeklyd,a,b,c
NCT03989232 · Phase 3
show 1 more dose
38.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Hypoglycemia Event Incidence
responder rate · % of participants
40% (n=365) vs 42.5% (n=365) Insulin Glarginea,b,h
NCT02058160 · Phase 3 · registry result, not featured evidence
2 other source trials
25.6% (n=469) vs 23.6% (n=467) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
6.4% (n=233) vs 23.6% (n=467) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
1.7% (n=300) vs 1% (n=299) Dulaglutide1.0 mgd,a,b,h
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.7% (n=301) vs 1% (n=299) Dulaglutide0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
PPG Excursion
absolute change · mmol/L
-3.9 vs -0.47 Insulin Glargine mmol/L @ 30wka,b
NCT02058160 · Phase 3 · registry result, not featured evidence
2 other source trials
-2.31 vs -0.18 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-3.23 vs -0.18 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 Sitagliptin mmol/L @ 30wk1.0 mg weeklyd,a,b
NCT03061214 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1 vs -0.7 Sitagliptin mmol/L @ 30wk0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
-1.5 vs -0.6 Insulin Glargine mmol/L @ 30wka,b
NCT02058160 · Phase 3 · registry result, not featured evidence
2 other source trials
-3.35 vs -2.66 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-1.95 vs -2.66 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-3.3 vs -1.6 Sitagliptin mmol/L @ 30wk1.0 mg weeklyd,a,b
NCT03061214 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.5 vs -1.6 Sitagliptin mmol/L @ 30wk0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
No placebo or comparator arm
-1.1 mmol/L @ 24wkd,a,b,g
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.8 mmol/L @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-1.69 mmol/L @ 52wka,b,g
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Waist Circumference Change
absolute change · cm
-1.4 vs -1.93 Liraglutide cm @ 8wk20 µgi,j,b,k
NCT01596504 · Phase 2 · registry result, not featured evidence
-12.6 vs -6.5 placebo cm @ 72wk7.2 mgi,j,b,k
NCT05649137 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-2.8 kg @ 24wkd,e,a,b
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.6 kg @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-5.3 kg @ 24wke,a,b
NCT05533632 · Phase 4 · registry result, not featured evidence
Weight Loss 5%
responder rate · % of participants
25.1% (n=295) vs 31.4% (n=296) Exenatide @ 24wkf,a,g
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
8 other source trials
19.7% (n=188) vs 14.7% (n=191) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
5.1% (n=217) vs 3.2% (n=220) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
9.2% (n=315) vs 5.1% (n=157) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
13.2% (n=311) vs 3.1% (n=161) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
14.4% (n=554) vs 7.2% (n=278) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
19.6% (n=158) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
25.8% (n=155) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
7.3% (n=150) vs 4.5% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
52.7% (n=298) vs 47% (n=313) Canagliflozin @ 52wkf,a,g
Yes
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
19.3% (n=249) @ 24wkd,a,b,c
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
14.9% (n=248) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
59.2% (n=480) @ 40wk2.0 mg weeklyd,a,b,c
NCT03989232 · Phase 3
show 1 more dose
51.3% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Dropout rate
32.5%l
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.2%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
8.3%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
3.5%
NCT01147250 · Phase 3
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.8%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
10.5%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
11.9%
NCT01798706 · Phase 3 · registry result, not featured evidence
10.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
10.6%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
16%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
8.7%
NCT01169779 · Phase 3 · registry result, not featured evidence
13%
NCT00975286 · Phase 3 · registry result, not featured evidence
26%
NCT00763815 · Phase 3 · registry result, not featured evidence
27.5%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
22.4%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
10.1%
NCT00976937 · Phase 3 · registry result, not featured evidence
35.3%
NCT00715624 · Phase 3 · registry result, not featured evidence
30.9%
NCT00713830 · Phase 3 · registry result, not featured evidence
18.6%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
24.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
25%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
39.4%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
13.6%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
4.2%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
6.8%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
1.3%1.0 mgm
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
14.1%l
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
2.5%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
4.2%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
—
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.3%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
3.9%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
—
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
8.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
5%
NCT01768559 · Phase 3 · registry result, not featured evidence
4.9%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
4.4%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
5.6%
NCT01169779 · Phase 3 · registry result, not featured evidence
8.5%
NCT00975286 · Phase 3 · registry result, not featured evidence
9%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
2.5%
NCT00976937 · Phase 3 · registry result, not featured evidence
11.2%
NCT00715624 · Phase 3 · registry result, not featured evidence
12.4%
NCT00713830 · Phase 3 · registry result, not featured evidence
8.7%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
11.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
13.9%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
21.2%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
9.1%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
2.1%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
3.7%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
—1.0 mgm
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
8.2%l
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
0%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
0.8%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
20.6%
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.2%
NCT05413369 · Phase 3 · registry result, not featured evidence
3.9%Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
10.2%Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
5.5%
NCT02058160 · Phase 3 · registry result, not featured evidence
3.8%Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
3.9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
4.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
3.7%
NCT01768559 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
1.5%
NCT01169779 · Phase 3 · registry result, not featured evidence
7.6%
NCT00975286 · Phase 3 · registry result, not featured evidence
7.7%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
1.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
14%
NCT00715624 · Phase 3 · registry result, not featured evidence
10.1%
NCT00713830 · Phase 3 · registry result, not featured evidence
—Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
13%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
9.9%Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
2.8%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.1%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.5%
NCT00866658 · Phase 3 · registry result, not featured evidence
2.1%20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
—20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
5.6%
NCT01476475 · Phase 2 · registry result, not featured evidence
0%
NCT01175473 · Phase 2 · registry result, not featured evidence
33.6%1.0 mgm
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
l
nausea 28.6%
nasopharyngitis 15.4%
diarrhoea 15.1%
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 31 more results
nausea 20.2% (placebo 3.3%)
headache 7.6% (placebo 8.2%)
vomiting 6.7% (placebo 0%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 24.2% (placebo 3.3%)
headache 8.3% (placebo 8.2%)
dizziness 7.5% (placebo 3.3%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 21.7% (placebo 5.9%)
hypoglycaemia 20.1% (placebo 18.3%)
dizziness 8.5% (placebo 6.3%)
NCT01147250 · Phase 3
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 17.2%
covid-19 13.4%
nausea 12.1%
NCT05413369 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.8%
nausea 8.6%
diarrhoea 5.5%
NCT02787551 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
nausea 9.2%
diarrhoea 7.3%
NCT02787551 · Phase 3 · registry result, not featured evidence
mild asymptomatic hypoglycaemia 33.3%
hypercholesterolaemia 22.2%
mild gastrointestinal complaints 22.2%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
nausea 10.4%
nasopharyngitis 8.8%
headache 5.8%
NCT02058160 · Phase 3 · registry result, not featured evidence
nausea 9.6%
diarrhoea 9%
upper respiratory tract infection 7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 24%
diarrhoea 9%
headache 7.7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 25% (placebo 7.5%)
hypoglycaemia 17% (placebo 10.3%)
diarrhoea 10.8% (placebo 7.5%)
NCT01798706 · Phase 3 · registry result, not featured evidence
hypoglycaemia 35.9%
nausea 25.2%
blood glucose decreased 20.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
nausea 15.5%
headache 7.1%
nasopharyngitis 7.1%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 14.7%
nasopharyngitis 9.8%
hypoglycaemia 6.7%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 16.3% (placebo 2.6%)
hypoglycaemia 9.2% (placebo 4.6%)
dizziness 8.7% (placebo 4.1%)
NCT01169779 · Phase 3 · registry result, not featured evidence
hypoglycaemia 27.4% (placebo 19.3%)
nausea 27.4% (placebo 4.9%)
headache 9.9% (placebo 3.6%)
NCT00975286 · Phase 3 · registry result, not featured evidence
nausea 26% (placebo 13.7%)
nasopharyngitis 16.4% (placebo 14.9%)
headache 13.3% (placebo 11.8%)
NCT00763815 · Phase 3 · registry result, not featured evidence
nausea 24.7% (placebo 10.6%)
headache 16.5% (placebo 23.5%)
vomiting 15.7% (placebo 3.5%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 25.1% (placebo 10.6%)
headache 19.2% (placebo 23.5%)
diarrhoea 15.3% (placebo 11.8%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 17.7%
headache 12.7%
diarrhoea 8.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
hypoglycaemia 42.1% (placebo 40.7%)
nausea 29.3% (placebo 9.6%)
headache 12.5% (placebo 10.2%)
NCT00715624 · Phase 3 · registry result, not featured evidence
nausea 28% (placebo 8.8%)
hypoglycaemia 24.4% (placebo 19.3%)
nasopharyngitis 15.9% (placebo 20.4%)
NCT00713830 · Phase 3 · registry result, not featured evidence
nausea 37.9% (placebo 8.1%)
vomiting 18% (placebo 0.6%)
diarrhoea 14.9% (placebo 13.1%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 29.2% (placebo 8.1%)
vomiting 13% (placebo 0.6%)
headache 12.4% (placebo 12.5%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 50%
nasopharyngitis 36.1%
decreased appetite 19.4%
NCT00905255 · Phase 3 · registry result, not featured evidence
nausea 36.4%
nasopharyngitis 27.3%
decreased appetite 18.2%
NCT00905255 · Phase 3 · registry result, not featured evidence
hypoglycaemia 43.5% (placebo 23.6%)
nausea 39.6% (placebo 4.5%)
vomiting 18.2% (placebo 1.9%)
NCT00866658 · Phase 3 · registry result, not featured evidence
20 µg
decreased appetite 18.8%
nausea 18.8%
nasopharyngitis 12.5%
NCT01596504 · Phase 2 · registry result, not featured evidence
nausea 7.5%
nasopharyngitis 5.6%
headache 5%
NCT01476475 · Phase 2 · registry result, not featured evidence
nausea 22.1%
decreased appetite 18.2%
headache 11.7%
NCT01175473 · Phase 2 · registry result, not featured evidence
1.0 mgm
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 40 weeks versus 24 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fThe reported result categories differ.
  7. gAssessment timepoints differ: 52 weeks versus 24 weeks.
  8. hThe assessment timepoint is not available for both results.
  9. iTrial phases differ: Phase 3 versus Phase 2.
  10. jPopulation context differs: registered conditions differ.
  11. kAssessment timepoints differ: 72 weeks versus 8 weeks.
  12. lPopulation comparability has not been reviewed for 32 of these studies.
  13. mPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

lixisenatide

Glycemic Rescue 2.2% (n=315) vs 3.8% (n=315) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
5.2% (n=291) vs 6.9% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
2.7% (n=366) vs 6% (n=365) Insulin Glargine
NCT02058160 · Phase 3 · registry result, not featured evidence
3.6% (n=468) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4% (n=233) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
2.9% (n=175) vs 10.4% (n=173) placebo @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
3.6% (n=195) vs 6.7% (n=193) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
0.4% (n=223) vs 0.4% (n=223) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
3.8% (n=320) vs 11.3% (n=159) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
9.5% (n=158) vs 6.8% (n=161) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
5.8% (n=327) vs 7.2% (n=166) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
4% (n=570) vs 12.6% (n=286) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
3.1% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=154) vs 3.2% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
0% (n=161) vs 0.6% (n=162) Insulin Glargine @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
PPG 2H -4.51 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 1 more result
-5.47 mmol/L @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
Glycemic Rescue 1.7% (n=120) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 3 more results
0.8% (n=118) @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=255) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
3.9% (n=255) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
Time to First MACE 13.4% (n=3034) vs 13.2% (n=3034) placebo
event count · % of participants
NCT01147250 · Phase 3 · converted to % from 406 participants as posted
Time to Cardiovascular MACE 15% (n=3034) vs 15.5% (n=3034) placebo
event count · % of participants
NCT01147250 · Phase 3 · converted to % from 456 participants as posted
UACR 24.17% (n=2803) vs 34.21% (n=2830) placebo @ 108wk
percent change · % of baseline
NCT01147250 · Phase 3
Time in Range 24 h 26.22 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV 5% (n=113) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -2.91 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -52.48 mg/dL as posted
PMG Change mg/dL -73.66 mg/dL @ 16wk
absolute change · mg/dL
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Time Above 180 -28.67 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV Less Than 36 76% (n=100) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence

+ 54 further endpoints in the CSV export.

Semaglutide (Ozempic)

MACE 3-point Composite 6.6% (n=1648) vs 8.9% (n=1649) placebo
event count · % of participants
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 1 more result
12% (n=1767) vs 14.4% (n=1766) placebo*
NCT03819153 · Phase 3 · converted to % from 212 Participants as posted
HbA1c 6.5 or Less 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk1.0 mg
event count · % of participants
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Renal Death 0.3% (n=1767) vs 0.3% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
UACR 0.6 vs 0.89 placebo ratio @ 104wk
ratio to baseline · ratio
NCT03819153 · Phase 3
Non-fatal MI 2.9% (n=1767) vs 3.6% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
MALE 0.9% (n=1767) vs 1.6% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
SBP -5.17 vs -1.68 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 13 more results
-4.3 vs -3.7 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-4.3 vs 1.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-4.65 vs -1.68 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-8 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-3 vs 0 placebo mmHg @ 34wk21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
-6 vs 0 placebo mmHg @ 34wk2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-10 vs 0 placebo mmHg @ 34wk2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-9 vs 0 placebo mmHg @ 34wk2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-13 vs 0 placebo mmHg @ 34wk2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
-3.9 vs -1.4 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-2.3 vs -1.8 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-4 vs -1 placebo mmHg @ 52wk
NCT04560998 · Phase 3 · registry result, not featured evidence
DBP -0.98 vs -1.44 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 7 more results
-1.5 vs -1.3 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-1.38 vs -1.44 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-3 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.8 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-1.6 vs -0.9 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
SBP -5.61 vs -2.29 Sitagliptin mmHg @ 56wk1.0 mg weekly
absolute change · mmHg
Systolic blood pressure
NCT01930188 · Phase 3 · combination
show 1 more result
-5.07 vs -2.29 Sitagliptin mmHg @ 56wk0.5 mg weekly
Systolic blood pressure
NCT01930188 · Phase 3 · combination

+ 100 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · Semaglutide (Ozempic)'s landscape